<DOC>
	<DOC>NCT02583438</DOC>
	<brief_summary>The intestinal microflora imbalance has been associated with obesity and type 2 diabetes. The researchers' study aimed to investigate the effect of saxagliptin on gut microbiota in patients with newly diagnosed type 2 diabetes.</brief_summary>
	<brief_title>Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Females or males, and aged 20 to 65 years. Newly diagnosed type 2 diabetes HbA1C ≥7% and HbA1C ＜9% Hepatic insufficiency (ALT or AST&gt; 1.5*ULN) Renal insufficiency [Creatinine clearance rate (Ccr)]&lt;60ml/min estimated from MDRD equation) Coronary artery disease Thyroid disease Infectious disease Systemic inflammatory disease Cancer Subjects who were taking agents known to influence gut microbiota Pregnant or lactating woman Other conditions at investigator's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Gut Microbiota</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>Glucose and lipid metabolism</keyword>
</DOC>